JPH09503387A - クローン化されたグルタミン酸デカルボキシラーゼ - Google Patents
クローン化されたグルタミン酸デカルボキシラーゼInfo
- Publication number
- JPH09503387A JPH09503387A JP7509191A JP50919195A JPH09503387A JP H09503387 A JPH09503387 A JP H09503387A JP 7509191 A JP7509191 A JP 7509191A JP 50919195 A JP50919195 A JP 50919195A JP H09503387 A JPH09503387 A JP H09503387A
- Authority
- JP
- Japan
- Prior art keywords
- gad
- polypeptide
- cells
- amino acid
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091022930 Glutamate decarboxylase Proteins 0.000 title description 8
- 102000008214 Glutamate decarboxylase Human genes 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 233
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 192
- 229920001184 polypeptide Polymers 0.000 claims abstract description 149
- 238000000034 method Methods 0.000 claims abstract description 77
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 19
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 10
- 150000001413 amino acids Chemical group 0.000 claims description 73
- 210000004027 cell Anatomy 0.000 claims description 66
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 49
- 239000012634 fragment Substances 0.000 claims description 28
- 239000000523 sample Substances 0.000 claims description 27
- 230000004044 response Effects 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 18
- 230000005867 T cell response Effects 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 12
- 210000004408 hybridoma Anatomy 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 206010003591 Ataxia Diseases 0.000 claims description 6
- 108090001090 Lectins Proteins 0.000 claims description 6
- 102000004856 Lectins Human genes 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 239000002523 lectin Substances 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 230000000638 stimulation Effects 0.000 claims description 6
- 229940104230 thymidine Drugs 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 239000003053 toxin Substances 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 108700012359 toxins Proteins 0.000 claims description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 239000013610 patient sample Substances 0.000 claims description 3
- 150000002739 metals Chemical class 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 230000004700 cellular uptake Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 53
- 229940024606 amino acid Drugs 0.000 description 53
- 241000699670 Mus sp. Species 0.000 description 51
- 239000000427 antigen Substances 0.000 description 45
- 108091007433 antigens Proteins 0.000 description 41
- 102000036639 antigens Human genes 0.000 description 41
- 239000002299 complementary DNA Substances 0.000 description 39
- 108090000623 proteins and genes Proteins 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 27
- 210000004556 brain Anatomy 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 24
- 206010012601 diabetes mellitus Diseases 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 description 21
- 238000004519 manufacturing process Methods 0.000 description 20
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 17
- 230000003053 immunization Effects 0.000 description 17
- 238000002649 immunization Methods 0.000 description 16
- 230000027455 binding Effects 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 230000006472 autoimmune response Effects 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 210000004153 islets of langerhan Anatomy 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 210000004989 spleen cell Anatomy 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 108010005774 beta-Galactosidase Proteins 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 230000001363 autoimmune Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000003018 immunoassay Methods 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 230000009257 reactivity Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 8
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000006166 lysate Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000005784 autoimmunity Effects 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000001114 immunoprecipitation Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- -1 polyethylene Polymers 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 210000001787 dendrite Anatomy 0.000 description 5
- 229930195712 glutamate Natural products 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 210000001640 nerve ending Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000000376 autoradiography Methods 0.000 description 4
- 238000011957 budget and coverage analysis Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 210000001638 cerebellum Anatomy 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 206010013023 diphtheria Diseases 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000009696 proliferative response Effects 0.000 description 4
- 230000003393 splenic effect Effects 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 102100032378 Carboxypeptidase E Human genes 0.000 description 3
- 108010058255 Carboxypeptidase H Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000709687 Coxsackievirus Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 210000003523 substantia nigra Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000003568 synaptosome Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- 241000611421 Elia Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 101100223310 Homo sapiens GAD1 gene Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000607715 Serratia marcescens Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000037516 chromosome inversion disease Diseases 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000005567 liquid scintillation counting Methods 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000956 olfactory bulb Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000001768 subcellular fraction Anatomy 0.000 description 2
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- OQPDPIPLWCUACY-UHFFFAOYSA-N 2-aminoethylthiourea;hydrobromide Chemical compound [Br-].NCC[NH+]=C(N)S OQPDPIPLWCUACY-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 101000868806 Bos taurus Carboxypeptidase E Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 244000102216 Crateva tapia Species 0.000 description 1
- 235000003495 Crateva tapia Nutrition 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 240000006497 Dianthus caryophyllus Species 0.000 description 1
- 235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 244000046038 Ehretia acuminata Species 0.000 description 1
- 235000009300 Ehretia acuminata Nutrition 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- 102100021118 Microtubule-associated protein 2 Human genes 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 101001044455 Rattus norvegicus Interferon gamma Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229920004929 Triton X-114 Polymers 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
- DKLRSEXTALBASW-UHFFFAOYSA-I [Cl-].[Th+4].[Na+].[Cl-].[Cl-].[Cl-].[Cl-] Chemical group [Cl-].[Th+4].[Na+].[Cl-].[Cl-].[Cl-].[Cl-] DKLRSEXTALBASW-UHFFFAOYSA-I 0.000 description 1
- GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical compound [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000002053 acidogenic effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000677 aggregate cell Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940096384 chicken egg white lysozyme Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 101150086609 groEL2 gene Proteins 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- JCDWETOKTFWTHA-UHFFFAOYSA-N methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=CC=C1 JCDWETOKTFWTHA-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 239000012713 reactive precursor Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rehabilitation Therapy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 から成る群から選ばれたアミノ酸配列から本質的に成るポリペプチド。 2.請求項1に記載のポリペプチドをコードする単離ポリヌクレオチド配列。 3.DNAである、請求項2に記載のポリヌクレオチド。 4.患者試料中のGADについする自己抗体の検出方法であって、その試料をGAD 断片と接触させ、そして自己抗体がその断片に結合するかどかを決定することを 含んで成る方法。 5.断片が、長さ少なくとも約16アミノ酸のポリペプチドであり、そしてGAD のアミノ酸約224〜アミノ酸585のアミノ酸配列から選ばれる、請求項4に記載の 方法。 6.断片が、請求項1に記載のポリペプチドである、請求項4に記載の方法。 7.試料が血液である請求項4に記載の方法。 8.ペプチドが検出可能な状態で標識付けれれている、請求項4に記載の方法 。 9.検出可能な標識が、ラジオアイソトープ、蛍光化合物、コロイド状金属、 化学発光化合物、生物発光化合物、リン光化合物、及び酵素から成る群から選ば れる、請求項8に記載の方法。 10.ペプチドが、固相に結合されている、請求項4に記載の方法。 11.請求項1に記載のペプチドに対するモノクローナル抗体。 12.請求項9に記載のモノクローナル抗体を産生することができるハイブリド ーマ・セルライン。 13.請求項2に記載のポリヌクレオチドを含むベクター。 14.請求項2に記載のポリヌクレオチドにより形質転換された宿主細胞。 15.GAD関連自己免疫疾患をもつ又はもつ危険のある患者においてその疾患を 改善する方法であって、その患者に治療的有効量の、全体GAD65又は治療的に有 効なその断片を投与することを含んで成る方法。 16.治療的に有効な断片が、長さ少なくとも約16のアミノ酸のポリペプチドで あり、そしてGAD65のアミノ酸約224〜アミノ酸約585のアミノ酸配列から選ばれ るる、請求項15に記載の方法。 17.治療的に有効な断片が から成る群から選ばれる、請求項15に記載の方法。 18.治療的に有効な断片が から成る群から選ばれる、請求項15に記載の方法。 19.失調がIDDMである、請求項16に記載の方法。 20.失調がきついヒト疾患(stiff man disease)である、請求項16に記載の方 法。 21.投与が経腸である、請求項16に記載の方法。 22.経腸投与が経口である、請求項21に記載の方法。 23.投与が非経口である、請求項15又は16に記載の方法。 24.非経口投与が,皮下、筋中、腹腔内、腔内、経皮、経鼻、又は静脈注射に よる、請求項23に記載の方法。 25.投与が、約0.01mg/kg/投与量〜約2000mg/kg/投与量の投 与量におけるものである、請求項15に記載の方法。 26.ポリペプチドが治療的に標識付けれれている、請求項15に記載の方法。 27.治療的標識が、ラジオアイソトープ、薬物、レクチン、及び毒素から成る 群から選ばれる、請求項26に記載の方法。 28.患者においてGAD関連自己免疫失調の状態を検出する方法であって、その 患者のT−細胞を請求項1に記載の少なくとも1のポリペプチドに接触させ、そ してそのペプチドに対するそのT−細胞の応答を検出することを含んで成る方法 。 29.T−細胞の応答が刺激である、請求項26に記載の方法。 30.刺激が放射標識付けされたヌクレオチドの細胞取り込みにより計測される 、請求項27に記載の方法。 31.ヌクレオチドが3Hチミジンである、請求項30に記載の方法。 32.請求項1に記載のポリペプチドに対する抗体を、このような抗体を含む疑 いのある試料中で検出するのに有用なキットであって、請求項1に記載のポリペ プチドを含む容器を含んで成る1以上の容器をその内に閉じた領域内に受容する ように区画化された担体手段を含んで成るようなキット。 33.患者の試料中でGAD関連失調の状態を測定するのに有用なキットであって 、請求項1に記載のポリペプチドを含む容器を含んで成る1以上の容器をその内 に閉じた領域内に受容するように区画化された担体手段を含んで成るようなキッ ト。 34.GAD関連自己免疫失調をもつ又はもつ危険のある患者においてその失調を 検出ための方法であって、その患者に診断的に有効な量の、GAD65の診断的に有 効な断片を投与することを含んで成るような方法。 35.診断的に有効な断片が、長さ少なくとも約16アミノ酸のポリペプチドであ り、そしてGAD65のアミノ酸約34〜573のアミノ酸配列から選ばれている、請求項 34に記載の方法。 36.診断的に有効な断片が、 から成る群から選ばれる、請求項35に記載の方法。 37.失調がIDDMである、請求項35に記載の方法。 38.失調がきついヒト疾患(stiff man disease)である、請求項35に記載の方 法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US123,859 | 1980-02-22 | ||
US08/123,859 | 1993-09-17 | ||
US08/123,859 US5674978A (en) | 1990-09-21 | 1993-09-17 | Peptides derived from glutamic acid decarboxylase |
PCT/US1994/009478 WO1995007992A2 (en) | 1993-09-17 | 1994-08-24 | Cloned glutamic acid decarboxylase |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09503387A true JPH09503387A (ja) | 1997-04-08 |
JP3133339B2 JP3133339B2 (ja) | 2001-02-05 |
Family
ID=22411325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP07509191A Expired - Lifetime JP3133339B2 (ja) | 1993-09-17 | 1994-08-24 | クローン化されたグルタミン酸デカルボキシラーゼ |
Country Status (11)
Country | Link |
---|---|
US (5) | US5674978A (ja) |
EP (1) | EP0719340B1 (ja) |
JP (1) | JP3133339B2 (ja) |
KR (1) | KR100367943B1 (ja) |
AT (1) | ATE221125T1 (ja) |
AU (1) | AU697058B2 (ja) |
CA (1) | CA2170523C (ja) |
DE (1) | DE69431060T2 (ja) |
DK (1) | DK0719340T3 (ja) |
ES (1) | ES2179077T3 (ja) |
WO (1) | WO1995007992A2 (ja) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992004632A1 (en) | 1990-09-07 | 1992-03-19 | The Regents Of The University Of California | Methods for the diagnosis and treatment of diabetes |
US6682906B1 (en) * | 1990-09-21 | 2004-01-27 | The Regents Of The University Of California | Cloned glutamic acid decarboxylase |
US5674978A (en) * | 1990-09-21 | 1997-10-07 | The Regents Of The University Of California | Peptides derived from glutamic acid decarboxylase |
CA2103159A1 (en) * | 1991-05-15 | 1992-11-16 | Ake Lernmark | Cloning and expression of human islet glutamic acid decarboxylase autoantigen |
DE69334246D1 (de) * | 1992-12-03 | 2008-12-24 | Univ California | Verbesserte reagentien und methoden zur diagnose und behandlung von diabetes und stiff man syndrome |
CA2140591A1 (en) * | 1994-01-20 | 1995-07-21 | Josef Endl | Antigen-specific, activated t lymphocytes, detection and use |
JP3778936B2 (ja) * | 1995-02-20 | 2006-05-24 | アムラド・オペレイションズ・プロプライエタリー・リミテッド | インシュリン依存性糖尿病(iddm)患者に作用する免疫反応および免疫治療分子 |
US5840307A (en) * | 1995-03-31 | 1998-11-24 | Immulogic Pharmacuetical Corp. | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation |
US5945401A (en) * | 1995-06-23 | 1999-08-31 | Conlon; Paul J. | Peptide analogues of the 65KD isoform of human glutamic acid decarboxylase and uses thereof |
DE19525784A1 (de) * | 1995-07-14 | 1997-01-16 | Boehringer Mannheim Gmbh | Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD) |
DE19526561A1 (de) * | 1995-07-20 | 1997-01-23 | Boehringer Mannheim Gmbh | In-vivo-Diabetes-Test |
AU2044197A (en) * | 1996-04-01 | 1997-10-22 | Chugai Seiyaku Kabushiki Kaisha | Diagnostic composition for diseases accompanied by autoimmune reactions caused by 65k-glutamic acid decarboxylase |
US7361331B2 (en) | 1996-10-18 | 2008-04-22 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | Plant bioreactors |
US6815174B1 (en) * | 1996-11-28 | 2004-11-09 | Edgardo Poskus | Thioredoxin-glutamate decarboxylase 65 fusion protein |
FR2759701B1 (fr) * | 1997-02-19 | 1999-06-04 | Inst Nat Sante Rech Med | Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques |
WO1999020295A1 (en) * | 1997-10-17 | 1999-04-29 | Trustees Of The University Of Pennsylvania | Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator |
SE9704451D0 (sv) * | 1997-11-28 | 1997-11-28 | Diamyd Therapeutics Ab | New method and compositions for the treatment of autoimmune diseases |
WO1999037315A1 (en) * | 1998-01-27 | 1999-07-29 | Bai Jane Pei Fan | Chemical derivatives of autoantigens and autoimmune-suppressive peptides and pharmaceutical composition containing the same |
US6303325B1 (en) | 1998-05-29 | 2001-10-16 | Dade Behring Inc. | Method for detecting analytes |
US6232082B1 (en) | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
AU775484C (en) * | 1999-08-23 | 2005-02-17 | Benaroya Research Institute At Virginia Mason | Peptide and peptide analogues for the treatment and prevention of diabetes |
US6436401B1 (en) | 1999-09-14 | 2002-08-20 | Milkhaus Laboratory, Inc. | Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies |
US6713058B2 (en) * | 1999-09-14 | 2004-03-30 | Milkhaus Laboratory, Inc. | Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies |
DE50114032D1 (de) * | 2000-04-10 | 2008-07-31 | Merk Und Kollegen Gmbh Lab Dr | Fusionsprotein zur gleichzeitigen Erkennung von humanen Autoantikörpern |
CA2406496A1 (en) | 2000-04-19 | 2001-11-01 | Research Corporation Technologies, Inc. | Diagnostic assay for endometriosis |
US7178152B2 (en) * | 2001-03-01 | 2007-02-13 | Sony Corporation | Application programming interface for communication between audio/video file system and audio video controller |
EP2302391A1 (en) * | 2001-04-10 | 2011-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic and diagnostic uses of antibody specificity profiles in rheumatoid arthritis |
US20050130245A1 (en) * | 2001-09-17 | 2005-06-16 | Syn X Pharma, Inc. | Diagnosis and treatment of early pre-type-1 diabetes utilizing neuronal proteins |
EP1545598A2 (en) * | 2002-10-02 | 2005-06-29 | Diamyd Medical AB | Formulation of glutamic acid decarboxylase (gad65) and serum albumin |
US20050250691A1 (en) * | 2004-05-10 | 2005-11-10 | Diamyd Therapeutics Ab | Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes |
EP1755631A2 (en) * | 2004-03-03 | 2007-02-28 | Diamyd Medical AB | Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes |
US20050209138A1 (en) * | 2004-03-19 | 2005-09-22 | Diamyd Therapeutics Ab | Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes |
WO2007114959A2 (en) * | 2006-04-04 | 2007-10-11 | University Of Toledo | Altered peptide ligands of gad65 |
CN100450552C (zh) * | 2006-05-26 | 2009-01-14 | 中国医学科学院医学生物学研究所 | Ⅰ型糖尿病疫苗及其构建方法 |
EP2049660A2 (en) * | 2006-08-01 | 2009-04-22 | Neurologix, Inc. | Novel glutamic acid decarboxylase (gad) proteins and methods of use |
WO2008070222A2 (en) * | 2006-08-21 | 2008-06-12 | Cytotrend Biotech Engineering Limited Usa Inc | A method of surface plasmon resonance (spr) technology to detect genomic disorders for prenatal diagnosis |
WO2008036465A2 (en) * | 2006-09-18 | 2008-03-27 | CMED Technologies Ltd. Office of Walkers Limited | A method to assess cancer susceptibility and differential diagnosis of metastases of unknown primary tumors |
GB2454852B (en) * | 2006-09-19 | 2011-06-29 | Limited Cmed Technologies | A method for screening of infectious agents in blood |
WO2008036474A2 (en) * | 2006-09-21 | 2008-03-27 | Cmed Technologies Ltd. | A method to detect tumor markers and diagnosis of undifferenciated tumors |
WO2008070223A2 (en) * | 2006-09-21 | 2008-06-12 | Cmed Technologies Ltd. | A method to remove repetitive sequences from human dna |
US20100041018A1 (en) * | 2006-09-25 | 2010-02-18 | Cmed Technologies Ltd. | Method to detect virus related immunological markers for the diagnosis of hepatitis c virus infection |
US20100028856A1 (en) * | 2006-09-25 | 2010-02-04 | Cmed Technologies Ltd. | Method to detect virus related immunological markers for the diagnosis of hepatitis b virus infection |
WO2008094312A2 (en) * | 2006-09-25 | 2008-08-07 | Cmed Technologies Ltd. | A method of surface plasmon resonance (spr) technology to detect genomic disorders for postnatal diagnosis |
US8158342B2 (en) * | 2006-09-25 | 2012-04-17 | Cmed Technologies Ltd. | Method for the identification of human immunodeficiency virus related antibodies in blood |
US8119350B2 (en) * | 2006-09-25 | 2012-02-21 | Cmed Technologies Ltd | Method of surface plasmon resonance (SPR) to detect genomic aberrations in patients with multiple myeloma |
US20090311699A1 (en) * | 2006-09-25 | 2009-12-17 | Cmed Technologies Ltd. | Method of surface plasmon resonance (spr) to detect genomic aberrations in patients with chronic lymphocytic leukemia |
WO2008066994A2 (en) * | 2006-09-27 | 2008-06-05 | Cmed Technologies Ltd. | Application of surface plasmon resonance technology to maternal serum screening for congenital birth defects |
WO2008066996A2 (en) * | 2006-09-27 | 2008-06-05 | Cmed Technologies Ltd. | A method to detect treponema pallidum immunological markers for the diagnosis of syphilis |
US8114682B2 (en) * | 2006-09-27 | 2012-02-14 | Cmed Technologies Ltd. | Method for the quantitative evaluation of sex hormones in a serum sample |
WO2008066997A2 (en) * | 2006-09-27 | 2008-06-05 | Cmed Technologies Ltd. | A method for quantitative measurement of cardiac biochemical markers |
WO2008067003A2 (en) * | 2006-09-27 | 2008-06-05 | Cmed Technologies Ltd. | A method to detect virus related immunological markers for the diagnosis of respiratory tract infections |
WO2008070241A2 (en) * | 2006-09-27 | 2008-06-12 | Cmed Technologies Ltd. | A method to measure serum biomarkers for the diagnosis of liver fibrosis |
US8158440B2 (en) * | 2006-09-28 | 2012-04-17 | Cmed Technologies Ltd. | Method for quantitative measurement of thyroid related antibodies or antigens in a serum sample |
GB2456690B (en) * | 2006-09-28 | 2012-01-25 | Cytotrend Biotech Engineering Ltd Usa Inc | A method for quantitative detection of diabetes related immunological markers |
JP5378202B2 (ja) * | 2007-03-15 | 2013-12-25 | 株式会社リバース・プロテオミクス研究所 | 脳・神経に特異的あるいは神経分化に特異的なバイオマーカー |
BRPI0823327A2 (pt) | 2007-03-16 | 2013-10-22 | Genomatica Inc | Biocatalisadores microbianos que não ocorrem naturalmente e métodos para a biosíntese de ácido 4-hidroxibutanóico e 1,4-butanodiol |
WO2008129426A2 (en) * | 2007-04-24 | 2008-10-30 | Diamyd Therapeutics Ab | Medicaments and methods to treat autoimmune disease and cancer |
US7947483B2 (en) | 2007-08-10 | 2011-05-24 | Genomatica, Inc. | Methods and organisms for the growth-coupled production of 1,4-butanediol |
EP2193206A4 (en) | 2007-10-04 | 2011-02-02 | Cmed Technologies Ltd | APPLICATION OF PLASMON SURFACE RESONANCE TECHNOLOGY FOR HPV DETECTION AND GENOTYPING |
WO2010030711A2 (en) | 2008-09-10 | 2010-03-18 | Genomatica, Inc. | Microorganisms for the production of 1,4-butanediol |
JP5851243B2 (ja) | 2008-11-30 | 2016-02-03 | イミューサンティー インコーポレーテッドImmusanT,Inc. | セリアック病の処置のための組成物および方法 |
MY195387A (en) | 2009-06-04 | 2023-01-18 | Genomatica Inc | Microorganisms for the Production of 1,4-Butanediol and Related Methods |
EP3199511B1 (en) | 2009-06-04 | 2020-01-29 | Genomatica, Inc. | Process of separating components of a fermentation broth |
CN105441374A (zh) | 2009-10-13 | 2016-03-30 | 基因组股份公司 | 生产1,4-丁二醇、4-羟基丁醛、4-羟基丁酰-coa、腐胺和相关化合物的微生物及其相关方法 |
US8530210B2 (en) | 2009-11-25 | 2013-09-10 | Genomatica, Inc. | Microorganisms and methods for the coproduction 1,4-butanediol and gamma-butyrolactone |
US8637286B2 (en) | 2010-02-23 | 2014-01-28 | Genomatica, Inc. | Methods for increasing product yields |
US8048661B2 (en) | 2010-02-23 | 2011-11-01 | Genomatica, Inc. | Microbial organisms comprising exogenous nucleic acids encoding reductive TCA pathway enzymes |
US8852873B2 (en) | 2012-04-13 | 2014-10-07 | Diabetomics, Llc | Maternal biomarkers for gestational diabetes |
BR112014030202A2 (pt) | 2012-06-04 | 2017-09-12 | Genomatica Inc | microorganismos e métodos para a produção de 4-hidroxibutirato 1,4-butanodiol e compostos relacionados |
EP3043812A1 (en) | 2013-09-10 | 2016-07-20 | Immusant Inc. | Dosage of a gluten peptide composition |
CN106535926B (zh) * | 2014-06-04 | 2022-02-01 | 戴尔米德医疗公司 | 用于基于抗原的疗法的新型组合物 |
WO2016054038A1 (en) | 2014-09-29 | 2016-04-07 | Immusant, Inc. | Use of hla genetic status to assess or select treatment of celiac disease |
AU2015349728A1 (en) | 2014-11-21 | 2017-07-13 | Immusant, Inc. | Peptides for use in treatment and diagnosis of type 1 diabetes |
TWI655812B (zh) | 2016-07-20 | 2019-04-01 | 松下知識產權經營股份有限公司 | 懸吊型插座 |
GB202210967D0 (en) * | 2022-07-27 | 2022-09-07 | Univ Birmingham | Tolerogenic peptides i |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4624926A (en) * | 1981-01-02 | 1986-11-25 | The Research Foundation Of State University Of New York | Novel cloning vehicles for polypeptide expression in microbial hosts |
US4487830A (en) * | 1982-05-14 | 1984-12-11 | American Hoechst Corporation | Enzyme/immunofluorescent assay for autoantibodies |
CA1247080A (en) * | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
US4751181A (en) * | 1984-12-31 | 1988-06-14 | Duke University | Methods and compositions useful in the diagnosis and treatment of autoimmune diseases |
US5645998A (en) * | 1988-12-13 | 1997-07-08 | University Of Florida Research Foundation | Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus |
US6001360A (en) * | 1988-12-13 | 1999-12-14 | University Of Florida | Method and compositions for early detection and treatment of insulin dependent diabetes mellitus |
US5762937A (en) * | 1988-12-13 | 1998-06-09 | University Of Florida Research Foundation, Inc. | Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus |
DE68924354T2 (de) * | 1988-12-13 | 1996-02-22 | Univ Florida | Verfahren und zusammensetzungen zur früherkennung von behandlung der insulinabhängigen diabetes mellitus(iddm). |
US5227159A (en) * | 1989-01-31 | 1993-07-13 | Miller Richard A | Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies |
NO306996B1 (no) * | 1989-02-17 | 2000-01-24 | Bayer Ag | Isolert bukspyttkjerteloey-celle-(ICA)-antigen for in vitro- bruk |
US5114844A (en) * | 1989-03-14 | 1992-05-19 | Yeda Research And Development Co., Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus |
ATE144326T1 (de) * | 1990-08-17 | 1996-11-15 | Univ Florida | Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes |
US5512447A (en) * | 1990-09-07 | 1996-04-30 | The Regents Of The University Of California | Methods for the diagnosis and treatment of diabetes |
US5674978A (en) * | 1990-09-21 | 1997-10-07 | The Regents Of The University Of California | Peptides derived from glutamic acid decarboxylase |
US5475086A (en) * | 1990-09-21 | 1995-12-12 | The Regents Of The University Of California | Cloned glutamic acid decarboxylase peptides |
AU8864791A (en) * | 1990-10-02 | 1992-04-28 | Trigen Incorporated | Antibodies and methods for diagnosis and treatment of diabetes |
DK0572478T3 (da) * | 1991-02-22 | 2006-01-16 | Inst Medical W & E Hall | HBGAD- og HIGAD-polypeptider og nukleinsyre og anvendelse heraf til diagnostik og behandling af GAD-autoantigen-associerede sygdomme |
CA2103159A1 (en) * | 1991-05-15 | 1992-11-16 | Ake Lernmark | Cloning and expression of human islet glutamic acid decarboxylase autoantigen |
AU661684B2 (en) * | 1991-06-18 | 1995-08-03 | Regents Of The University Of California, The | Cloned glutamic acid decarboxylase |
US5200318A (en) * | 1992-05-13 | 1993-04-06 | Miles Inc. | Diagnosis of IDDM with a panel of immunoreagents |
US5837477A (en) * | 1993-01-15 | 1998-11-17 | The United States Of America As Represented By The Department Of Health And Human Services | T cell receptor ligands and methods of using same |
WO1994020127A1 (en) * | 1993-03-05 | 1994-09-15 | Cytel Corporation | Hla-a2.1 binding peptides and their uses |
US5547847A (en) * | 1993-09-07 | 1996-08-20 | University Of Washington | Diagnosis of insulin-dependent diabetes |
-
1993
- 1993-09-17 US US08/123,859 patent/US5674978A/en not_active Expired - Lifetime
-
1994
- 1994-08-24 KR KR1019960701348A patent/KR100367943B1/ko not_active IP Right Cessation
- 1994-08-24 EP EP94927940A patent/EP0719340B1/en not_active Expired - Lifetime
- 1994-08-24 AU AU79201/94A patent/AU697058B2/en not_active Expired
- 1994-08-24 ES ES94927940T patent/ES2179077T3/es not_active Expired - Lifetime
- 1994-08-24 JP JP07509191A patent/JP3133339B2/ja not_active Expired - Lifetime
- 1994-08-24 AT AT94927940T patent/ATE221125T1/de active
- 1994-08-24 DE DE69431060T patent/DE69431060T2/de not_active Expired - Lifetime
- 1994-08-24 CA CA2170523A patent/CA2170523C/en not_active Expired - Lifetime
- 1994-08-24 WO PCT/US1994/009478 patent/WO1995007992A2/en active IP Right Grant
- 1994-08-24 DK DK94927940T patent/DK0719340T3/da active
-
1995
- 1995-06-07 US US08/485,725 patent/US8926966B1/en active Active
- 1995-06-07 US US08/483,952 patent/US6011139A/en not_active Expired - Lifetime
- 1995-06-07 US US08/476,501 patent/US6455267B1/en not_active Expired - Lifetime
- 1995-09-22 US US08/484,530 patent/US5846740A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6011139A (en) | 2000-01-04 |
US8926966B1 (en) | 2015-01-06 |
JP3133339B2 (ja) | 2001-02-05 |
AU697058B2 (en) | 1998-09-24 |
US6455267B1 (en) | 2002-09-24 |
ES2179077T3 (es) | 2003-01-16 |
EP0719340B1 (en) | 2002-07-24 |
WO1995007992A2 (en) | 1995-03-23 |
EP0719340A1 (en) | 1996-07-03 |
DK0719340T3 (da) | 2002-11-18 |
US5846740A (en) | 1998-12-08 |
CA2170523A1 (en) | 1995-03-23 |
DE69431060T2 (de) | 2002-11-14 |
CA2170523C (en) | 2010-03-30 |
AU7920194A (en) | 1995-04-03 |
WO1995007992A3 (en) | 1995-06-22 |
KR960705051A (ko) | 1996-10-09 |
DE69431060D1 (de) | 2002-08-29 |
KR100367943B1 (ko) | 2003-06-18 |
US5674978A (en) | 1997-10-07 |
ATE221125T1 (de) | 2002-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09503387A (ja) | クローン化されたグルタミン酸デカルボキシラーゼ | |
KR100220277B1 (ko) | 클로닝된 글루탐산 탈탄산 효소 | |
US5998366A (en) | Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders | |
Rudy et al. | Similar peptides from two β cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes | |
US5705626A (en) | Cloned glutamic acid decarboxylase nucleic acids | |
JPH06510903A (ja) | 自己免疫疾患の診断および治療 | |
WO2007034489A2 (en) | Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom | |
JP3554319B2 (ja) | ペプチドp277類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物 | |
AU661828B2 (en) | Methods and compositions for early detection and treatment of insulin dependent diabetes mellitus | |
JP4072922B2 (ja) | クローン化グルタミン酸デカルボキシラーゼ | |
AU2003232751A1 (en) | Immunoglobulin conjugates of autoantigens and their use in the prevention of disease | |
NZ282118A (en) | Use of a v<beta>6.1, v<beta>6/6.7 or v<beta>14 containing t cell receptors to treat diabetes | |
AU657501C (en) | Cloned glutamic acid decarboxylase used in the detection of IDDM | |
AU727683B2 (en) | Cloned glutamic acid decarboxylase | |
Christie | ISLET PROTEINS INMPLICATED| N PATHOGENESIS OF TYPE | |
Smith | edmonTon, ALBeRTA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081124 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091124 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091124 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101124 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111124 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121124 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131124 Year of fee payment: 13 |
|
EXPY | Cancellation because of completion of term |